Impax Laboratories (IPXL) Receives Price Target

Impax Laboratories (IPXL) : 8 Wall Street analysts covering Impax Laboratories (IPXL) believe that the average level the stock could reach for the short term is $28. The maximum price target given is $32 and the minimum target for short term is around $24, hence the standard deviation is calculated at $3.16.

Impax Laboratories (IPXL) : Zacks Investment Research ranks Impax Laboratories (IPXL) as 3, which is a Hold recommendation. 3 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. A total of 6 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 9 research analysts is 2.33, which indicates as a Buy.


Also, Brokerage firm Northland Securities upgrades its rating on Impax Laboratories (NASDAQ:IPXL). The shares have been rated Outperform. Previously, the analysts had a Market Perform rating on the shares. The rating by the firm was issued on August 15, 2016.

Impax Laboratories (NASDAQ:IPXL): The stock opened at $24.23 on Thursday but the bulls could not build on the opening and the stock topped out at $24.40 for the day. The stock traded down to $23.71 during the day, due to lack of any buying support eventually closed down at $23.94 with a loss of -1.03% for the day. The stock had closed at $24.19 on the previous day. The total traded volume was 838,186 shares.

Impax Laboratories, Inc. is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. The Company operates in two segments: Impax Generics and Impax Specialty Pharma. The Impax Generics is focused on the development, manufacture, sale and distribution of the Companys generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are marketed under their established drug names. The Impax Specialty Pharma is engaged in the development of brand pharmaceutical products for the treatment of central nervous system (CNS) disorders. The Impax Specialty Pharma is also engaged in the sale and distribution of Zomig (zolmitriptan) products, indicated for the treatment of migraine headaches.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.